AI Stock Analysis: Is It Time to Invest in CLDI?

June 3, 12:11 pm

Calidi Biotherapeutics is a biopharmaceutical company specializing in the development of immuno-oncology therapies. The company focuses on using engineered viral vectors to target and destroy cancer cells. This innovative approach has shown promise in preclinical trials and has the potential to revolutionize cancer treatment.

Fundamental Analysis

The revenue for the last quarter was $0. This represents a decrease of 100.00% compared to the previous quarter, which is a significant red flag. Furthermore, this is also a 100.00% decrease when compared to the same quarter last year, raising considerable concerns about the company's ability to generate income.

However, the net income for the last quarter was $7.2M, an increase of 12.20% compared to the quarter before it. This is a promising sign of growth and effective cost management. However, it's essential to note that compared to the same quarter last year, there is an 11.81% decrease in net income, which could be a concern over the longer term.

The EBITDA for the last quarter was $0, which is consistent both with the previous quarter and the same quarter last year. This indicates stability but also raises questions about profitability, considering the lack of revenue.

Technical Analysis

Today's stock price stands at $0.20, equal to the price a month ago, signifying short-term stability. However, compared to one year ago, this represents a steep decline of 98.08%, which is alarming for long-term investors. The overall trend appears to be bearish.

The current 10-day Simple Moving Average (SMA10) is $0.23, which is lower than the previous SMA10. This suggests a potential downward trend in the stock's price movement, raising concerns for short-term market behavior.

The Relative Strength Index (RSI) is at 50, indicating a neutral condition. This suggests that the stock is neither overbought nor oversold, providing no clear indication of impending price movement.

Alternative Data Analysis

According to data from popular job boards, Calidi Biotherapeutics currently has 0 open positions, and this number has remained stable over the last couple of months. This suggests stability within the company, neither expanding nor contracting its workforce significantly.

The website traffic has increased, with an estimated 6,000 visitors, up by 50% in the last couple of months. This bullish trend could indicate rising interest and potential customer acquisition.

Furthermore, the company has 51 followers on its Twitter page, with a 70% increase in followers recently. This uptick in social media engagement can be a positive indicator of growing public interest and support.

Finally, according to AltIndex's AI score, which predicts stock price movements based on fundamental, technical, and alternative data, Calidi Biotherapeutics has a score of 57. This is a 'hold' signal, suggesting that the stock is not currently a strong buy or sell candidate.

Conclusion and Recommendation

Calidi Biotherapeutics presents a mixed bag of indicators. The company shows stability in certain aspects such as EBITDA and employee numbers, but there are significant red flags regarding revenue generation and long-term stock price performance. Positive signs in net income growth and increased web traffic and social media engagement indicate some underlying strength and potential for recovery.

Based on the diverse data considered, the recommendation is to hold the stock. The 'hold' signal from AltIndex’s AI score aligns with the mixed fundamental and technical indicators. Investors should keep an eye on future developments, particularly any new revenue streams or significant business updates, that could alter the investment outlook.

Disclaimer: This article, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current. Visit CLDI AI Stock Analysis for a more up-to-date analysis.

Get More Insights

Sign up and get access to a personalized dashboard, deeper insights, AI stock picks, stock alerts, weekly newsletter and much more.